Evidence map›Paper›PMID 25057899›Full record

ArticlePloS one2014

Design, synthesis and pharmacological evaluation of novel vanadium-containing complexes as antidiabetic agents.

Elena V Fedorova, Anna V Buryakina, Alexey V Zakharov, Dmitry A Filimonov, Alexey A Lagunin, Vladimir V Poroikov

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A Dioxidovanadium ComplexEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elena V FedorovaSaint-Petersburg State Chemical Pharmaceutical Academy, Ministry of Healthcare and Social Development of Russian Federation, Saint-Petersburg, Russian Federation.
Anna V BuryakinaSaint-Petersburg State Chemical Pharmaceutical Academy, Ministry of Healthcare and Social Development of Russian Federation, Saint-Petersburg, Russian Federation.
Alexey V ZakharovNational Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America; Orekhovich Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow, Russian Federation.
Dmitry A FilimonovOrekhovich Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow, Russian Federation.
Alexey A LaguninOrekhovich Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow, Russian Federation.
Vladimir V PoroikovOrekhovich Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Moscow, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the data about structure and antidiabetic activity of twenty seven vanadium and zinc coordination complexes collected from literature we developed QSAR models using the GUSAR program. These QSAR models were applied to 10 novel vanadium coordination complexes designed in silico in order to predict their hypoglycemic action. The five most promising substances with predicted potent hypoglycemic action were selected for chemical synthesis and pharmacological evaluation. The selected coordination vanadium complexes were synthesized and tested in vitro and in vivo for their hypoglycemic activities and acute rat toxicity. Estimation of acute rat toxicity of these five vanadium complexes was performed using a freely available web-resource (http://way2drug.com/GUSAR/acutoxpredict.html). It has shown that the selected compounds belong to the class of moderate toxic pharmaceutical agents, according to the scale of Hodge and Sterner. Comparison with the predicted data has demonstrated a reasonable correspondence between the experimental and predicted values of hypoglycemic activity and toxicity. Bis{tert-butyl[amino(imino)methyl]carbamato}oxovanadium (IV) and sodium(2,2'-Bipyridyl)oxo-diperoxovanadate(V) octahydrate were identified as the most potent hypoglycemic agents among the synthesized compounds.

Indexed as

AdipocytesAnimalsCoordination ComplexesDrug DesignEpinephrineHyperglycemiaHypoglycemic AgentsInhibitory Concentration 50MaleMiceMolecular StructurePrimary Cell CultureQuantitative Structure-Activity RelationshipRatsRats, WistarVanadium(2,2'-bipyridyl)oxodiperoxovanadate(V)bis(tert-butyl(amino(imino)methyl)carbamato)oxovanadium(IV)Coordination ComplexesEpinephrineHypoglycemic AgentsVanadium

Identifiers

PMID25057899
PMCPMC4109918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.